Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Zsófia D. Drobni(Semmelweis University), Tomas G. Neilan(Albert Einstein College of Medicine), Hannah Gilman(Massachusetts General Hospital), Leyre Zubiri(Massachusetts General Hospital), Udo Hoffmann(Duke Medical Center), Rayma C. Mosarla(Massachusetts General Hospital), Kerry L. Reynolds(Massachusetts General Hospital), Jana Taron(University Medical Center Freiburg), Sean Murphy(Massachusetts General Hospital), Thomas Mayrhofer(Harvard University), Vineet K. Raghu(Massachusetts General Hospital), Daniel A. Zlotoff(Massachusetts General Hospital), Amna Zafar(Massachusetts General Hospital), Jingyi Gong(Massachusetts General Hospital), Charlotte Lee(Massachusetts General Hospital), Lili Zhang(Guangxi Medical University), Raza M. Alvi(Massachusetts General Hospital), Paula Rambarat(Massachusetts General Hospital), Sarah Hartmann(Massachusetts General Hospital), Ryan J. Sullivan(Dana-Farber Cancer Institute)
Cited by 535
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Narcolepsy in orexin Knockout Mice
|Cell|1999|3.1k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k